ArticleTherapeutic advances in medical oncology2022

A phase Ib/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT).

Charlotte I Stroes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.